Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Upgraded by Zacks Research

Vanda Pharmaceuticals (NASDAQ:VNDA) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

VNDA has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Monday. B. Riley Financial reiterated a “buy” rating and set a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Oppenheimer assumed coverage on Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wall Street Zen raised Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 31st. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Vanda Pharmaceuticals Trading Down 7.5%

VNDA opened at $3.59 on Wednesday. The stock has a market capitalization of $217.09 million, a P/E ratio of -0.78 and a beta of 0.74. Vanda Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $9.94. The firm’s fifty day simple moving average is $4.66 and its 200 day simple moving average is $6.14. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. The firm had revenue of $69.81 million during the quarter, compared to analysts’ expectations of $69.20 million. As a group, research analysts anticipate that Vanda Pharmaceuticals will post -2.53 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Large investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at about $46,841,000. Monaco Asset Management SAM bought a new stake in Vanda Pharmaceuticals during the second quarter worth about $1,354,000. State Street Corp raised its holdings in Vanda Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock worth $21,520,000 after acquiring an additional 500,843 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Vanda Pharmaceuticals during the second quarter valued at approximately $1,317,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in Vanda Pharmaceuticals during the first quarter valued at approximately $1,668,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Director Charles Cliff Duncan bought a combined 10,000 shares from November 3–5 for approximately $38,069, increasing his ownership. SEC ownership filing
• Neutral Sentiment: HC Wainwright maintained its Buy rating and raised its 2026 EPS estimate to a loss of $2.45 from a loss of $3.03, including a narrower projected Q4 loss.
• Negative Sentiment: HC Wainwright lowered estimates for Q2–Q4 2027 and cut its full-year 2027 EPS forecast to a loss of $1.02 from a loss of $0.94, signaling a less favorable outlook for those periods.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.